Claims for Patent: 8,431,380

Summary for Patent: 8,431,380

Title:	Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
Abstract:	The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP\'s), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
Inventor(s):	Bookbinder; Louis (San Diego, CA), Kundu; Anirban (San Diego, CA), Frost; Gregory I. (Del Mar, CA)
Assignee:	Halozyme, Inc. (San Diego, CA)
Application Number:	12/378,984
Patent Claims:	1. A substantially purified hyaluronidase polypeptide selected from: a) a polypeptide that consists of the sequence of amino acids set forth as amino acid residues 36-482 of SEQ ID NO:1, or b) a polypeptide that consists of a sequence of amino acids that has at least 99% sequence identity with the polypeptide of a), wherein: the hyaluronidase polypeptides of a) and b) contain at least one sugar moiety that is covalently attached to an asparagine residue of the hyaluronidase polypeptide; and the polypeptide is catalytically active. 2. A substantially purified hyaluronidase polypeptide selected from: a) a hyaluronidase polypeptide that comprises residues 36-464 of SEQ ID NO:1, and is C-terminally truncated so that it does not include the full-length of the polypeptide whose sequence is set forth in SEQ ID NO:1, or b) a hyaluronidase polypeptide that contains amino acid substitutions in the sequence of amino acids of the C-terminally truncated polypeptide of a), whereby the amino acid-substituted hyaluronidase polypeptide consists of a sequence of amino acids that has at least 91% amino acid sequence identity to a polypeptide with a sequence of a), wherein: the hyaluronidase polypeptide contains at least one sugar moiety that is covalently attached to an asparagine residue of the hyaluronidase polypeptide; the polypeptide is catalytically active; and the polypeptide is truncated at an amino acid residue selected from among residues 477, 478, 479, 480, 481, 482 and 483 of SEQ ID NO:1. 3. The substantially purified hyaluronidase polypeptide of claim 2, wherein the polypeptide is secreted when produced in CHO cells. 4. A substantially purified hyaluronidase polypeptide of claim 2, wherein the polypeptide is modified with a polymer. 5. A substantially purified hyaluronidase polypeptide of claim 4, wherein the polymer is a polyethylene glycol (PEG) or a dextran. 6. A pharmaceutical composition, comprising a substantially purified hyaluronidase polypeptide of claim 2. 7. The pharmaceutical composition of claim 6, wherein the polypeptide is produced by expression in mammalian cells of a nucleic acid molecule that encodes amino acids 36-482 of SEQ ID NO:1. 8. The pharmaceutical composition of claim 7, wherein the mammalian cell is a CHO cell. 9. The pharmaceutical composition of claim 6, further comprising a pharmaceutically active agent. 10. The pharmaceutical composition of claim 9, wherein the pharmaceutically active agent is a small molecule. 11. The pharmaceutical composition of claim 9, wherein the pharmaceutically active agent is selected from among a chemotherapeutic agent, an analgesic agent, an anti-inflammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonocidal agent, an anti-parkinson agent, an anti-malarial agent, an anti-convulsant agent, an anti-depressant agent, and antiarthritics agent, an anti-fungal agent, an antihypertensive agent, an antipyretic agent, an anti-parasite agent, an antihistamine agent, an alpha-adrenargic agonist agent, an alpha blocker agent, an anesthetic agent, a bronchial dialator agent, a biocide agent, a bactericide agent, a bacteriostat agent, a beta adrenergic blocker agent, a calcium channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, a electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a sedative agent, a sympathomimetic agent, a tranquilizer agent, a viricide agent, a vitamin agent, a non-steroidal anti-inflammatory agent, an angiotensin converting enzyme inhibitor agent, and a sleep inducer. 12. The pharmaceutical composition of claim 11, wherein the chemotherapeutic agent is a toxin or a tumor necrosis factor. 13. The pharmaceutical composition of claim 11, wherein the anesthetic agent is lidocaine or bupivacaine. 14. The pharmaceutical composition of claim 9, further comprising a hormonal agent. 15. The pharmaceutical composition of claim 14, wherein the hormonal agent is epinephrine. 16. The pharmaceutical composition of claim 9, wherein the pharmaceutically active agent is selected from among an insulin, a cytokine, an antibody and a monoclonal antibody. 17. A conjugate, comprising: a polypeptide of claim 2 linked directly or indirectly via a linker to a targeting agent. 18. A kit, comprising: a first composition, comprising the hyaluronidase polypeptide of claim 2; and a second composition, comprising a pharmaceutically active agent, wherein the first and second compositions are separate or combined to form a single composition. 19. The kit of claim 18, wherein the pharmaceutically active agent is a small molecule. 20. The kit of claim 18, wherein the pharmaceutically active agent is selected from among a chemotherapeutic agent, an analgesic agent, an anti-inflammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonocidal agent, an anti-parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, and antiarthritics agent, an anti-fungal agent, an antihypertensive agent, an antipyretic agent, an anti-parasite agent, an antihistamine agent, an alpha-adrenargic agonist agent, an alpha blocker agent, an anesthetic agent, a bronchial dilator agent, a biocide agent, a bactericide agent, a bacteriostat agent, a beta adrenergic blocker agent, a calcium channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, a electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a sedative agent, a sympathomimetic agent, a tranquilizer agent, a viricide agent, a vitamin agent, a non-steroidal anti-inflammatory agent, an angiotensin converting enzyme inhibitor agent and a sleep inducer. 21. The kit of claim 18, wherein the pharmaceutically active agent is selected from among insulin, a cytokine, an antibody and a monoclonal antibody. 22. The substantially purified hyaluronidase polypeptide of claim 2, wherein the amino-acid substituted polypeptide of b) consists of a sequence of amino acids that has at least 95% amino acid sequence identity with a sequence of the polypeptide of a). 23. The substantially purified hyaluronidase polypeptide of claim 2 that contains amino acid substitutions in the sequence of amino acids of the C-terminally truncated polypeptide of a), whereby the amino acid-substituted hyaluronidase polypeptide consists of a sequence of amino acids that has at least 91% amino acid sequence identity with to a polypeptide of a). 24. The hyaluronidase polypeptide of claim 2 that is produced and secreted from a mammalian expression system. 25. The pharmaceutical composition of claim 9, wherein the pharmaceutically active agent is a corticosteroid. 26. The kit of claim 18, wherein the pharmaceutically active agent is a corticosteroid. 27. A liposome, comprising the polypeptide of claim 2. 28. The pharmaceutical composition of claim 6 that comprises a slow release delivery vehicle. 29. The pharmaceutical composition of claim 28, wherein the slow release delivery vehicle comprises a lipid-polymer conjugate. 30. The pharmaceutical composition of claim 8, where in the slow release delivery vehicle comprises a colloidal dispersion system. 31. The pharmaceutical composition of claim 30, wherein the colloidal dispersion system is a liposome or a microsphere. 32. The pharmaceutical composition of claim 28, wherein the slow release delivery vehicle comprises a biodegradable hydrogel matrix, a dendritic polymer or a multivesicular liposome. 33. A liposome, comprising the polypeptide of claim 1.

Details for Patent 8,431,380

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004		2023-03-05
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004		2023-03-05
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004		2023-03-05
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	October 25, 2005		2023-03-05
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859	December 02, 2005		2023-03-05

International Patent Family for US Patent 8,431,380

Country	Patent Number	Estimated Expiration
Austria	E448323
Australia	2004218354
Australia	2006216545
Australia	2009245838
Australia	2013202475